American Vanguard (NYSE:AVD) Director Buys $39,710.00 in Stock

American Vanguard Corporation (NYSE:AVD) Director Steven Macicek bought 19,000 shares of the company’s stock in a transaction on Monday, August 17th. The shares were bought at an average price of $2.09 per share, for a total transaction of $39,710.00. Following the transaction, the director owned 99,711 shares of the company’s stock, valued at approximately $208,395.99. This represents a 23.54% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

American Vanguard Stock Performance

Shares of NYSE AVD traded down $0.04 during mid-day trading on Tuesday, hitting $2.19. The company had a trading volume of 1,720,856 shares, compared to its average volume of 324,210. The company has a current ratio of 2.47, a quick ratio of 1.40 and a debt-to-equity ratio of 1.46. American Vanguard Corporation has a 1 year low of $2.03 and a 1 year high of $5.92. The company has a market capitalization of $64.75 million, a price-to-earnings ratio of -1.16 and a beta of 1.43. The stock’s 50-day moving average price is $2.62 and its 200-day moving average price is $3.17.

American Vanguard (NYSE:AVD) last issued its quarterly earnings data on Monday, August 10th. The basic materials company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.43). The company had revenue of $116.75 million for the quarter, compared to analysts’ expectations of $135.00 million. American Vanguard had a negative return on equity of 9.05% and a negative net margin of 10.70%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on AVD shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of American Vanguard in a research note on Thursday. Wall Street Zen lowered shares of American Vanguard from a “hold” rating to a “sell” rating in a research report on Saturday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. raised its stake in American Vanguard by 15.0% in the third quarter. Russell Investments Group Ltd. now owns 22,456 shares of the basic materials company’s stock valued at $129,000 after purchasing an additional 2,921 shares in the last quarter. Barclays PLC grew its stake in American Vanguard by 3.6% in the 4th quarter. Barclays PLC now owns 126,269 shares of the basic materials company’s stock worth $482,000 after buying an additional 4,391 shares in the last quarter. Strs Ohio bought a new position in shares of American Vanguard in the 1st quarter worth $28,000. Gamco Investors INC. ET AL increased its holdings in shares of American Vanguard by 13.3% in the 1st quarter. Gamco Investors INC. ET AL now owns 68,000 shares of the basic materials company’s stock worth $169,000 after buying an additional 8,000 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in shares of American Vanguard by 46.2% during the 4th quarter. Wells Fargo & Company MN now owns 28,650 shares of the basic materials company’s stock valued at $109,000 after buying an additional 9,055 shares in the last quarter. Hedge funds and other institutional investors own 79.00% of the company’s stock.

About American Vanguard

American Vanguard Corporation (NYSE: AVD) is a developer, manufacturer and marketer of specialty chemical products for crop protection, turf and ornamental care, and public health pest control. Headquartered in Newport Beach, California, the company offers a portfolio of insecticides, herbicides, fungicides and rodenticides designed for use across agricultural, turf and urban pest management applications. Its research and development efforts focus on novel chemistries and formulation technologies that address emerging pest resistance and regulatory requirements.

The company’s product lines include emulsifiable concentrates, wettable powders, granular formulations, baits and liquid concentrates sold under proprietary brand names.